Skip to content
Menu
Home
About Us
Life Wins
Chairman’s Profile
Board Of Directors
Team Wockhardt
Corporate Milestones
Research & Development
R&D at Wockhardt
New Drug Discovery
Pipeline / Projects
News & Events
Publications
WCK 5222
WCK 4873
WCK 4282
WCK 6777
Biologicals
News & Events
Pipeline / Projects
Publications
R&D Contact
Our Business Verticals
Our Manufacturing Units
Global Footprint
India
UK & Europe
US
Emerging Markets
Products
India Branded Business
Trademark Products
Quality
Digital Footprint
Awards & Recognitions
Investors
From Chairman’s Office
AGM Speech
Letter to Shareowners
Financials
Financials at a Glance
Annual Report
Quarterly Results
Financial Press Releases
Related Party Transactions
Subsidiary Financials
Annual Return
Corporate Governance
Policies & Codes
Committee’s of the Board
Familiarisation programs
Shareholding Pattern
Secretarial Compliance Report
Authorised KMP
Corporate Actions
Announcements / Disclosures
Shareholders Meeting/ Postal ballot
AGM Notice
Proceedings
IEPF
Unclaimed Dividend
Nodal Officer
Analyst/ Investors
Presentation
Audio / Video Recording
Transcript
Shareowner Services
FAQ
Green Initiative
Investor Contact
Stock Quotes
Credit Rating
careers
Introduction
Life@Wockhardt
L&D Initiatives
Voice of Wockhardians
The Wockhardian
Career@Wockhardt
Media
Press Release
Media Coverage
Video Coverage
Media Kit
Sustainability
Contact us
Home
/
2015-2016
/
Page 3
PDF Year:
2015-2016
Home
For Quarter-ended Jun. 30, 2015
Wockhardt receives ANDA approval for Pain Medication Oxycodone Liquid
Wockhardt Annual Financial Results (FY 14 – 15)
Wockhardt receives QIDP designation for its new Drug WCK 4873 from U.S. FDA
Wockhardt Annual Financial Results (FY 2015 – 16)
Financial Results FY16 Q3
Financial Results FY 2015 – 16 Q2 (Jul – Sep 2015)
Financial Results FY 2015 – 16 Q1 (Apr – Jun 2015)
Posts navigation
Previous page
Page
1
Page
2
Page
3
